Menu

Moderna, Inc. MRNA

Full chart Compare
Set alert

Price alert · MRNA

All alert types
253.10 USD -15.90 (-5.91%)

Nov 10, 2026, 2:39 PM EST

251.40 Day range 273.00
22.28 52-week range 280.80
YTD
+758.26%
1 year
+922.21%
Market cap
102.49B
Revenue (ttm)
2.52B
Profit margin
-110.45%
EPS (ttm)
-7.04
Shares out
404.62M
Forward P/E
-62.90
YTD return
+758.26%
1-year return
+922.21%
Volume
7.76M
Avg volume
21.93M
Open
265.86
Previous close
269.00
Day's range
251.40 – 273.00
52-week range
22.28 – 280.80
Beta
1.17
Analysts
Hold
Price target
154.47 (-39.0%)
Earnings date
Feb 12, 2027

5D +19.12 (+8.17%)

240260280WedThuFriMonTue253.18

Key statistics

Enterprise value
101.91B
PEG ratio
0.00
Price / sales
43.11
Price / book
15.90
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
29.20%
Free cash flow
-584.50M
Total cash
5.17B
Total debt
4.23B
Return on equity
-34.50%
Short % of float
9.98%
50-day average
191.85
200-day average
91.47

Financials — quick view

All financials
MRNA Revenue — quarterly 1.31B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
MRNA Net income — quarterly 162.00M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
MRNA EPS — quarterly 0.40
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

MRNA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 12, 2027Dec 30, 2026-1.73———
Nov 6, 2026Sep 30, 2026-1.100.38+1.48+134.55%
Jul 31, 2026Jun 30, 2026-2.03-1.97+0.06+2.96%
May 1, 2026Mar 31, 2026-4.45-3.40+1.05+23.60%
Feb 13, 2026Dec 31, 2025-2.54-2.11+0.43+16.93%
Nov 6, 2025Sep 30, 2025-1.87-0.51+1.36+72.73%

Upgrades / downgrades

MRNA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 9, 2026Goldman SachsmainNeutralNeutral
Nov 9, 2026Piper SandlerreitOverweightOverweight
Oct 27, 2026William BlairdownOutperformMarket Perform
Oct 26, 2026Piper SandlerreitOverweightOverweight
Oct 21, 2026TD CowenmainHoldHold
Oct 15, 2026Goldman SachsmainNeutralNeutral

About Moderna, Inc.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on MRNA — it syncs with the Stock Master app.

Insider holders

MRNA insider holders
InsiderRelationLatest transactionDateShares held
AFEYAN NOUBAR BOGHOSDirectorSaleMay 20, 20260
BANCEL STEPHANE JChief Executive OfficerConversion of Exercise of derivative securityAug 5, 202622,215,800
HOGE STEPHENPresidentSaleSep 14, 20261,718,080
HORNING SANDRADirectorConversion of Exercise of derivative securityApr 29, 202618,585
HUSSAIN SHAH ABBASDirectorSaleApr 30, 202612,066
KLINGER SHANNON THYMEOfficerConversion of Exercise of derivative securitySep 3, 202681,340

Institution ownership

MRNA institution ownership
Holder% heldSharesValueReported
FMR, LLC12.99%51,859,89113.95BJun 29, 2026
Blackrock Inc.7.66%30,599,4098.23BJun 29, 2026
Vanguard Capital Management LLC5.81%23,208,7926.24BJun 29, 2026
Capital World Investors5.58%22,276,9965.99BJun 29, 2026
BAILLIE GIFFORD & CO4.56%18,206,7784.90BJun 29, 2026
State Street Corporation3.94%15,726,1934.23BJun 29, 2026

Fund ownership

MRNA fund ownership
Holder% heldSharesValueReported
Growth Fund of America3.75%14,983,2294.03BSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.84%11,331,6923.05BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.29%9,154,5102.46BJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund2.12%8,471,5752.28BSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.05%8,190,0722.20BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund1.30%5,187,9701.40BJun 29, 2026